The Synthetic Antimicrobial Peptide 19-2.5 Interacts with Heparanase and Heparan Sulfate in Murine and Human Sepsis
Open Access
- 23 November 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (11), e0143583
- https://doi.org/10.1371/journal.pone.0143583
Abstract
Heparanase is an endo-β-glucuronidase that cleaves heparan sulfate side chains from their proteoglycans. Thereby, heparanase liberates highly potent circulating heparan sulfate-fragments (HS-fragments) and triggers the fatal and excessive inflammatory response in sepsis. As a potential anti-inflammatory agent for sepsis therapy, peptide 19–2.5 belongs to the class of synthetic anti-lipopolysaccharide peptides; however, its activity is not restricted to Gram-negative bacterial infection. We hypothesized that peptide 19–2.5 interacts with heparanase and/or HS, thereby reducing the levels of circulating HS-fragments in murine and human sepsis. Our data indicate that the treatment of septic mice with peptide 19–2.5 compared to untreated control animals lowers levels of plasma heparanase and circulating HS-fragments and reduces heparanase activity. Additionally, mRNA levels of heparanase in heart, liver, lung, kidney and spleen are downregulated in septic mice treated with peptide 19–2.5 compared to untreated control animals. In humans, plasma heparanase level and activity are elevated in septic shock. The ex vivo addition of peptide 19–2.5 to plasma of septic shock patients decreases heparanase activity but not heparanase level. Isothermal titration calorimetry revealed a strong exothermic reaction between peptide 19–2.5 and heparanase and HS-fragments. However, a saturation character has been identified only in the peptide 19–2.5 and HS interaction. In conclusion, the findings of our current study indicate that peptide 19–2.5 interacts with heparanase, which is elevated in murine and human sepsis and consecutively attenuates the generation of circulating HS-fragments in systemic inflammation. Thus, peptide 19–2.5 seems to be a potential anti-inflammatory agent in sepsis.Keywords
This publication has 31 references indexed in Scilit:
- Peptide 19-2.5 Inhibits Heparan Sulfate-Triggered Inflammation in Murine Cardiomyocytes Stimulated with Human Sepsis SerumPLOS ONE, 2015
- Heparanase mediates renal dysfunction during early sepsis in micePhysiological Reports, 2013
- New Antiseptic Peptides To Protect against Endotoxin-Mediated ShockAntimicrobial Agents and Chemotherapy, 2010
- International Study of the Prevalence and Outcomes of Infection in Intensive Care UnitsJAMA, 2009
- Role of endothelial heparanase in delayed-type hypersensitivityBlood, 2006
- Inflammatory Cytokines and Fatty Acids Regulate Endothelial Cell Heparanase ExpressionBiochemistry, 2004
- Cutting Edge: An Endogenous Pathway to Systemic Inflammatory Response Syndrome (SIRS)-Like Reactions through Toll-Like Receptor 4Published by The American Association of Immunologists ,2004
- Cytokine modulation in sepsis and septic shockExpert Opinion on Investigational Drugs, 2002
- Receptor-Mediated Monitoring of Tissue Well-Being Via Detection of Soluble Heparan Sulfate by Toll-Like Receptor 4Published by The American Association of Immunologists ,2002
- The Danger Model: A Renewed Sense of SelfScience, 2002